Last reviewed · How we verify
Chang-Ming Huang, Prof. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akeso · 1 shared drug class
- Angion Biomedica Corp · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
- Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
- Centre Leon Berard · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- AB Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Chang-Ming Huang, Prof.:
- Chang-Ming Huang, Prof. pipeline updates — RSS
- Chang-Ming Huang, Prof. pipeline updates — Atom
- Chang-Ming Huang, Prof. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Chang-Ming Huang, Prof. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chang-ming-huang-prof. Accessed 2026-05-16.